Compare Danaher Corporation (DHR) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Lufax Holding Ltd — how do they compare? Danaher Corporation trades at $207 (market cap $147.18B), while Lufax Holding Ltd trades at $1.56 (market cap $2.41B). The key difference: Danaher Corporation is far larger — about 61.1× Lufax Holding Ltd's market cap, and Danaher Corporation pays a 0.76% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals.
| DHR | LU | |
|---|---|---|
Market Cap | $147.18B | $2.41B |
Sector | Health | Technology |
52-Week High | $242.05 | $4.40 |
52-Week Low | $161.91 | $1.23 |
Enterprise Value | $169.39B | — |
Dividend Yield | 0.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $207.44, up 1.31% today, near its pivot point of $207. The stock exhibits a bullish technical trend, supported by moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company maintains strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights the acquisition of Masimo and new product launches from its SCIEX unit, signaling growth initiatives.
The outlook remains positive with analyst consensus favoring a Buy rating and a $202.33 price target, though the current price exceeds this. Risks include a high P/E ratio of 37.32 and ongoing legal settlements, but robust cash flow and institutional accumulation provide support. Earnings growth in the biotechnology segment is a key catalyst for further upside.
LU trades at $1.50, up 0.67% on the day, with a neutral technical signal and bearish moving averages. The stock shows deep value on price-to-sales (0.42) and price-to-book (0.12) ratios but faces profitability challenges with a -9.08% net margin and negative ROE. Recent earnings misses and a securities class action lawsuit filed in May 2026 create headwinds, though analyst consensus remains 69% buy-rated.
The outlook is cautious due to litigation overhangs and persistent losses, but low valuations may attract value investors if operational improvements materialize. Key risks include legal liabilities and execution on turning profitability; upside depends on management's ability to stabilize earnings amid competitive pressures in Chinese financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
